Boya Bio-pharmaceutical Group Co Ltd - ESG Rating & Company Profile powered by AI
This Disclosure rating covers seventeen United Nations Sustainable Development Goals including: 'Affordable & Clean Energy', 'Responsible Production & Consumption' and 'Life below Water'. The ESG assessment for Boya Bio-pharmaceutical Group Co Ltd represents the company's transparency towards the United Nations Sustainable Development Goals. The report of Boya Bio-pharmaceutical Group Co Ltd leverages data from across the web as well as from available filings by Boya Bio-pharmaceutical Group Co Ltd.
Boya Bio-pharmaceutical Group Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1967 | Hospira Inc | 0.3 | Low |
1967 | PRA Health Sciences Inc | 0.3 | Low |
1970 | Boya Bio-pharmaceutical Group Co Ltd | 0.0 | Low |
1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
1970 | CTC Bio Inc | 0.0 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Boya Bio-pharmaceutical Group Co Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Boya Bio-pharmaceutical Group Co Ltd disclose current and historical energy intensity?
Does Boya Bio-pharmaceutical Group Co Ltd report the average age of the workforce?
Does Boya Bio-pharmaceutical Group Co Ltd reference operational or capital allocation in relation to climate change?
Does Boya Bio-pharmaceutical Group Co Ltd disclose its ethnicity pay gap?
Does Boya Bio-pharmaceutical Group Co Ltd disclose cybersecurity risks?
Does Boya Bio-pharmaceutical Group Co Ltd offer flexible work?
Does Boya Bio-pharmaceutical Group Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Boya Bio-pharmaceutical Group Co Ltd disclose the number of employees in R&D functions?
Does Boya Bio-pharmaceutical Group Co Ltd conduct supply chain audits?
Does Boya Bio-pharmaceutical Group Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Boya Bio-pharmaceutical Group Co Ltd conduct 360 degree staff reviews?
Does Boya Bio-pharmaceutical Group Co Ltd disclose the individual responsible for D&I?
Does Boya Bio-pharmaceutical Group Co Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Boya Bio-pharmaceutical Group Co Ltd disclose current and / or historical scope 2 emissions?
Does Boya Bio-pharmaceutical Group Co Ltd disclose water use targets?
Does Boya Bio-pharmaceutical Group Co Ltd have careers partnerships with academic institutions?
Did Boya Bio-pharmaceutical Group Co Ltd have a product recall in the last two years?
Does Boya Bio-pharmaceutical Group Co Ltd disclose incidents of discrimination?
Does Boya Bio-pharmaceutical Group Co Ltd allow for Work Councils/Collective Agreements to be formed?
Has Boya Bio-pharmaceutical Group Co Ltd issued a profit warning in the past 24 months?
Does Boya Bio-pharmaceutical Group Co Ltd disclose parental leave metrics?
Does Boya Bio-pharmaceutical Group Co Ltd disclose climate scenario or pathway analysis?
Does Boya Bio-pharmaceutical Group Co Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Boya Bio-pharmaceutical Group Co Ltd disclose the pay ratio of women to men?
Does Boya Bio-pharmaceutical Group Co Ltd support suppliers with sustainability related research and development?
Does Boya Bio-pharmaceutical Group Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Boya Bio-pharmaceutical Group Co Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Boya Bio-pharmaceutical Group Co Ltd involved in embryonic stem cell research?
Does Boya Bio-pharmaceutical Group Co Ltd disclose GHG and Air Emissions intensity?
Does Boya Bio-pharmaceutical Group Co Ltd disclose its waste policy?
Does Boya Bio-pharmaceutical Group Co Ltd report according to TCFD requirements?
Does Boya Bio-pharmaceutical Group Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Boya Bio-pharmaceutical Group Co Ltd disclose energy use targets?
Does Boya Bio-pharmaceutical Group Co Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Boya Bio-pharmaceutical Group Co Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Boya Bio-pharmaceutical Group Co Ltd
These potential risks are based on the size, segment and geographies of the company.
China Resources Boya Bio-pharmaceutical Group Co., Ltd. engages in the blood products, diabetes medication, biochemical medication, and chemical medicine businesses in China. It engages in the research and development, production, and sales of blood products comprising human fibrinogen, intravenous human immunoglobulin, rabies immunoglobulin, human albumin, human immunoglobulin, freeze-dried intravenous human immunoglobulin, and hepatitis B human immunoglobulin; diabetes products, including metformin hydrochloride tablets/enteric-coated tablets, pioglitazone hydrochloride dispersible tablets, glimepiride tablets, and calcium dobesilate capsules; and compound osteotide, oxytocin, and heparin sodium injections for various fields, such as medicine, hepatitis, gynecology, and immunomodulation. The company was formerly known as Boya Bio-pharmaceutical Group Co., Ltd. and changed its name to China Resources Boya Bio-pharmaceutical Group Co., Ltd. China Resources Boya Bio-pharmaceutical Group Co., Ltd. was founded in 1993 and is based in Fuzhou, China.